ERYPAR (erythromycin stearate) by Pfizer is clinical pharmacology orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Approved for the following infections caused by chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 5 more indications. First approved in 1977.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve optimal serum levels. Erythromycin is largely…
Worked on ERYPAR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.